Jack Yin Zheng

Jack is the Founding Partner of Trinity Innovation Bioventure Singapore (TIBS) and Trinity Innovation Fund (TIF). He is also the Chairman of TIBS. Previously, he served as the Managing Director of SDIC Innovation Investment Management Co., Ltd. where he was responsible for equity investments in the Pharmaceutical and Healthcare sector, such as CanSino, Ascentage, Bright-gene, Dizal, Ribo, and EpimAb. Prior to SDIC, Dr. Yin worked in both biotechnology and global multinational pharmaceutical companies Novartis where he lead and managed innovative drug discovery projects. His previous academic background includes positions as Dean of School of Pharmacy and Deputy Director of the State Key Laboratory of Medicinal Chemical Biology at Nankai University. He also acted as the Executive Director of the Center of Basic Molecular Science at Tsinghua University.

Jack holds a Ph.D. in Organic Chemistry from the National University of Singapore, and graduated with both M.Sc. and B.Sc. in Chemistry from Nankai University.